<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Michaela T Hall</style></author><author><style face="normal" font="default" size="100%">Kate T Simms</style></author><author><style face="normal" font="default" size="100%">John M Murray</style></author><author><style face="normal" font="default" size="100%">Adam Keane</style></author><author><style face="normal" font="default" size="100%">Diep T N Nguyen</style></author><author><style face="normal" font="default" size="100%">Michael Caruana</style></author><author><style face="normal" font="default" size="100%">Gigi Lui</style></author><author><style face="normal" font="default" size="100%">Helen Kelly</style></author><author><style face="normal" font="default" size="100%">Linda O Eckert</style></author><author><style face="normal" font="default" size="100%">Santesso, Nancy</style></author><author><style face="normal" font="default" size="100%">de Sanjosé, Silvia</style></author><author><style face="normal" font="default" size="100%">Edwin E Swai</style></author><author><style face="normal" font="default" size="100%">Ajay Rangaraj</style></author><author><style face="normal" font="default" size="100%">Owiredu, Morkor Newman</style></author><author><style face="normal" font="default" size="100%">Cindy Gauvreau</style></author><author><style face="normal" font="default" size="100%">Owen Demke</style></author><author><style face="normal" font="default" size="100%">Partha Basu</style></author><author><style face="normal" font="default" size="100%">M. Arbyn</style></author><author><style face="normal" font="default" size="100%">Shona Dalal</style></author><author><style face="normal" font="default" size="100%">Broutet, Nathalie</style></author><author><style face="normal" font="default" size="100%">Canfell, Karen</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Benefits and harms of cervical screening, triage and treatment strategies in women living with HIV.</style></title><secondary-title><style face="normal" font="default" size="100%">Nat Med</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Acetic Acid</style></keyword><keyword><style  face="normal" font="default" size="100%">Cervix Uteri</style></keyword><keyword><style  face="normal" font="default" size="100%">Early Detection of Cancer</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">HIV Infections</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Papillomavirus Infections</style></keyword><keyword><style  face="normal" font="default" size="100%">triage</style></keyword><keyword><style  face="normal" font="default" size="100%">Uterine Cervical Neoplasms</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2023 Dec</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">29</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;To support a strategy to eliminate cervical cancer as a public health problem, the World Health Organisation (WHO) reviewed its guidelines for screening and treatment of cervical pre-cancerous lesions in 2021. Women living with HIV have 6-times the risk of cervical cancer compared to women in the general population, and we harnessed a model platform ('Policy1-Cervix-HIV') to evaluate the benefits and harms of a range of screening strategies for women living with HIV in Tanzania, a country with endemic HIV. Assuming 70% coverage, we found that 3-yearly primary HPV screening without triage would reduce age-standardised cervical cancer mortality rates by 72%, with a number needed to treat (NNT) of 38.7, to prevent a cervical cancer death. Triaging HPV positive women before treatment resulted in minimal loss of effectiveness and had more favorable NNTs (19.7-33.0). Screening using visual inspection with acetic acid (VIA) or cytology was less effective than primary HPV and, in the case of VIA, generated a far higher NNT of 107.5. These findings support the WHO 2021 recommendation that women living with HIV are screened with primary HPV testing in a screen-triage-and-treat approach starting at 25 years, with regular screening every 3-5 years.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">12</style></issue></record></records></xml>